

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  
For the quarterly period ended September 30, 2021  
or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  
For the transition period from \_\_\_\_\_ to \_\_\_\_\_  
Commission file number 001-38961



**Change Healthcare Inc.**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State or Other Jurisdiction of Incorporation or Organization)  
**424 Church Street, Suite 1400**  
**Nashville, TN**  
(Address of Principal Executive Offices)

**82-2152098**  
(I.R.S. Employer Identification No.)

**37219**  
(Zip Code)

**(615) 932-3000**  
(Registrant's Telephone Number, Including Area Code)  
Securities registered pursuant to Section 12(b) of the Act:

Title of each class  
Common Stock, par value \$0.001 per share  
6.00% Tangible Equity Units

Trading Symbol(s)  
CHNG  
CHNGU

Name of each exchange on which registered  
The Nasdaq Stock Market LLC  
The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a Large Accelerated Filer, an Accelerated Filer, a Non-Accelerated Filer, a Smaller Reporting Company, or an Emerging Growth Company. See the definitions of "Large Accelerated Filer," "Accelerated Filer," "Smaller Reporting Company" and "Emerging Growth Company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer  Accelerated Filer  Non-Accelerated Filer   
Smaller Reporting company  Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

Number of shares of common stock outstanding on October 22, 2021: 311,495,269

## TABLE OF CONTENTS

<b>PART I. Financial Information</b>		
Item 1.	<a href="#">Financial Statements</a>	3
Item 2.	<a href="#">Management's Discussion and Analysis of Financial Condition and Results of Operations</a>	21
Item 3.	<a href="#">Quantitative and Qualitative Disclosures About Market Risk</a>	33
Item 4.	<a href="#">Controls and Procedures</a>	33
<b>PART II. Other Information</b>		
Item 1.	<a href="#">Legal Proceedings</a>	34
Item 1A.	<a href="#">Risk Factors</a>	34
Item 2.	<a href="#">Unregistered Sales of Equity Securities and Use of Proceeds</a>	34
Item 3.	<a href="#">Defaults Upon Senior Securities</a>	34
Item 4.	<a href="#">Mine Safety Disclosures</a>	35
Item 5.	<a href="#">Other Information</a>	35
Item 6.	<a href="#">Exhibits</a>	35
<a href="#">Signatures</a>		

**Part I. Financial Information**

**Item 1. Financial Statements**

**Change Healthcare Inc.**  
**Consolidated Statements of Operations**  
(unaudited and amounts in thousands, except share and per share amounts)

	Three Months Ended September 30,		Six Months Ended September 30,	
	2021	2020	2021	2020
<b>Revenue</b>				
Solutions revenue	\$ 774,214	\$ 705,913	\$ 1,590,862	\$ 1,354,325
Postage revenue	52,550	50,023	103,758	95,795
<b>Total revenue</b>	<b>826,764</b>	<b>755,936</b>	<b>1,694,620</b>	<b>1,450,120</b>
<b>Operating expenses</b>				
Cost of operations (exclusive of depreciation and amortization below)	346,632	326,653	698,695	645,195
Research and development	67,070	54,052	138,310	109,787
Sales, marketing, general and administrative	183,041	171,606	360,997	337,080
Customer postage	52,550	50,023	103,758	95,795
Depreciation and amortization	163,469	146,869	331,681	285,409
Accretion and changes in estimate with related parties, net	2,870	3,564	5,907	9,459
Gain on sale of businesses	—	(176)	—	(28,270)
<b>Total operating expenses</b>	<b>815,632</b>	<b>752,591</b>	<b>1,639,348</b>	<b>1,454,455</b>
<b>Operating income (loss)</b>	<b>11,132</b>	<b>3,345</b>	<b>55,272</b>	<b>(4,335)</b>
<b>Non-operating (income) expense</b>				
Interest expense, net	59,466	61,627	118,852	124,294
Loss on extinguishment of debt	2,232	1,489	2,232	1,489
Other, net	2,587	(3,761)	(605)	(1,953)
<b>Total non-operating (income) expense</b>	<b>64,285</b>	<b>59,355</b>	<b>120,479</b>	<b>123,830</b>
<b>Income (loss) before income tax provision (benefit)</b>	<b>(53,153)</b>	<b>(56,010)</b>	<b>(65,207)</b>	<b>(128,165)</b>
<b>Income tax provision (benefit)</b>	<b>(16,749)</b>	<b>(13,388)</b>	<b>(25,198)</b>	<b>(26,849)</b>
<b>Net income (loss)</b>	<b>\$ (36,404)</b>	<b>\$ (42,622)</b>	<b>\$ (40,009)</b>	<b>\$ (101,316)</b>
<b>Net income (loss) per share:</b>				
Basic and diluted	\$ (0.11)	\$ (0.13)	\$ (0.12)	\$ (0.32)
<b>Weighted average common shares outstanding:</b>				
Basic and diluted	324,060,460	320,638,116	323,309,280	320,347,128

See accompanying notes to consolidated financial statements.

**Change Healthcare Inc.**  
**Consolidated Statements of Comprehensive Income (Loss)**  
(unaudited and amounts in thousands)

	Three Months Ended September 30,		Six Months Ended September 30,	
	2021	2020	2021	2020
<b>Net income (loss)</b>	\$ (36,404)	\$ (42,622)	\$ (40,009)	\$ (101,316)
<b>Other comprehensive income (loss):</b>				
Foreign currency translation adjustment	(2,156)	5,221	1,415	11,574
Changes in fair value of interest rate caps, net of taxes	41	(1,996)	160	(6,180)
<b>Other comprehensive income (loss)</b>	(2,115)	3,225	1,575	5,394
<b>Total comprehensive income (loss)</b>	<u>\$ (38,519)</u>	<u>\$ (39,397)</u>	<u>\$ (38,434)</u>	<u>\$ (95,922)</u>

See accompanying notes to consolidated financial statements.

**Change Healthcare Inc.**  
**Consolidated Balance Sheets**  
(unaudited and amounts in thousands, except share and per share amounts)

	September 30, 2021	March 31, 2021
<b>Assets</b>		
<b>Current assets:</b>		
Cash & cash equivalents	\$ 80,414	\$ 113,101
Accounts receivable, net	704,595	732,614
Contract assets, net	128,010	132,856
Prepaid expenses and other current assets	149,176	140,258
<b>Total current assets</b>	<b>1,062,195</b>	<b>1,118,829</b>
Property and equipment, net	150,579	174,370
Operating lease right-of-use assets, net	80,562	93,412
Goodwill	4,110,823	4,108,792
Intangible assets, net	3,942,164	4,187,072
Other noncurrent assets, net	503,405	430,141
<b>Total assets</b>	<b>\$ 9,849,728</b>	<b>\$ 10,112,616</b>
<b>Liabilities</b>		
<b>Current liabilities:</b>		
Accounts payable	\$ 64,756	\$ 57,449
Accrued expenses	463,510	484,293
Deferred revenue	377,270	436,666
Due to related parties, net	11,392	10,766
Current portion of long-term debt	19,152	27,339
Current portion of operating lease liabilities	28,948	30,608
<b>Total current liabilities</b>	<b>965,028</b>	<b>1,047,121</b>
Long-term debt, excluding current portion	4,643,245	4,734,775
Long-term operating lease liabilities	62,001	75,396
Deferred income tax liabilities	578,584	605,291
Tax receivable agreement obligations due to related parties	97,606	103,151
Tax receivable agreement obligations	196,687	229,082
Other long-term liabilities	62,411	65,572
<b>Total liabilities</b>	<b>6,605,562</b>	<b>6,860,388</b>
<b>Commitments and contingencies</b>		
<b>Stockholders' Equity</b>		
Common Stock (par value, \$0.001), 9,000,000,000 and 9,000,000,000 shares authorized and 311,311,208 and 306,796,076 shares issued and outstanding at September 30, 2021 and March 31, 2021, respectively	311	307
Preferred stock (par value, \$0.001), 900,000,000 shares authorized and no shares issued and outstanding at both September 30, 2021 and March 31, 2021	—	—
Additional paid-in capital	4,313,759	4,283,391
Accumulated other comprehensive income (loss)	12,796	11,221
Accumulated deficit	(1,082,700)	(1,042,691)
<b>Total stockholders' equity</b>	<b>3,244,166</b>	<b>3,252,228</b>
<b>Total liabilities and stockholders' equity</b>	<b>\$ 9,849,728</b>	<b>\$ 10,112,616</b>

See accompanying notes to consolidated financial statements.

**Change Healthcare Inc.**  
**Consolidated Statements of Stockholders' Equity**  
(unaudited and amounts in thousands, except share and per share amounts)

	Common Stock		Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Total Stockholders' Equity
	Shares	Amount				
<b>Balance at March 31, 2020</b>	303,428,142	\$ 303	\$ 4,222,580	\$ (930,064)	\$ (7,372)	\$ 3,285,447
Cumulative effect of accounting change-ASU 2016-13	—	—	—	(417)	—	(417)
Equity compensation expense	—	—	8,780	—	—	8,780
Issuance of common stock under equity compensation plans	341,230	1	2,143	—	—	2,144
Net income (loss)	—	—	—	(58,694)	—	(58,694)
Foreign currency translation adjustment	—	—	—	—	6,353	6,353
Change in fair value of interest rate caps, net of taxes	—	—	—	—	(4,184)	(4,184)
Other	—	—	(75)	—	—	(75)
<b>Balance at June 30, 2020</b>	<u>303,769,372</u>	<u>\$ 304</u>	<u>\$ 4,233,428</u>	<u>\$ (989,175)</u>	<u>\$ (5,203)</u>	<u>\$ 3,239,354</u>
Equity compensation expense	—	—	12,372	—	—	12,372
Issuance of common stock under equity compensation plans	911,961	—	408	—	—	408
Employee tax withholding on vesting of equity compensation awards	(254,764)	—	(3,131)	—	—	(3,131)
Net income (loss)	—	—	—	(42,622)	—	(42,622)
Foreign currency translation adjustment	—	—	—	—	5,221	5,221
Change in fair value of interest rate caps, net of taxes	—	—	—	—	(1,996)	(1,996)
Other	—	—	(356)	—	—	(356)
<b>Balance at September 30, 2020</b>	<u>304,426,569</u>	<u>\$ 304</u>	<u>\$ 4,242,721</u>	<u>\$ (1,031,797)</u>	<u>\$ (1,978)</u>	<u>\$ 3,209,250</u>
<b>Balance at March 31, 2021</b>	306,796,076	\$ 307	\$ 4,283,391	\$ (1,042,691)	\$ 11,221	\$ 3,252,228
Equity compensation expense	—	—	23,191	—	—	23,191
Issuance of common stock under equity compensation plans	1,948,163	2	1,443	—	—	1,445
Employee tax withholding on vesting of equity compensation awards	(564,116)	(1)	(13,015)	—	—	(13,016)
Net income (loss)	—	—	—	(3,605)	—	(3,605)
Foreign currency translation adjustment	—	—	—	—	3,571	3,571
Change in fair value of interest rate caps, net of taxes	—	—	—	—	119	119
Conversion of tangible equity units	2,497,813	3	(3)	—	—	—
Other	—	—	(80)	—	—	(80)
<b>Balance at June 30, 2021</b>	<u>310,677,936</u>	<u>\$ 311</u>	<u>\$ 4,294,927</u>	<u>\$ (1,046,296)</u>	<u>\$ 14,911</u>	<u>\$ 3,263,853</u>
Equity compensation expense	—	—	23,776	—	—	23,776
Issuance of common stock under equity compensation plans	896,107	—	1,031	—	—	1,031
Employee tax withholding on vesting of equity compensation awards	(262,835)	—	(5,985)	—	—	(5,985)
Net income (loss)	—	—	—	(36,404)	—	(36,404)
Foreign currency translation adjustment	—	—	—	—	(2,156)	(2,156)
Change in fair value of interest rate caps, net of taxes	—	—	—	—	41	41
Conversion of tangible equity units	—	—	—	—	—	—
Other	—	—	10	—	—	10
<b>Balance at September 30, 2021</b>	<u>311,311,208</u>	<u>\$ 311</u>	<u>\$ 4,313,759</u>	<u>\$ (1,082,700)</u>	<u>\$ 12,796</u>	<u>\$ 3,244,166</u>

See accompanying notes to consolidated financial statements.

**Change Healthcare Inc.**  
**Consolidated Statements of Cash Flows**  
**(unaudited and amounts in thousands)**

	Six Months Ended	
	September 30,	
	2021	2020
<b>Cash flows from operating activities:</b>		
Net income (loss)	\$ (40,009)	\$ (101,316)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:		
Depreciation and amortization	331,681	285,409
Amortization of capitalized software developed for sale	1,576	89
Accretion and changes in estimate, net	9,087	11,188
Equity compensation	49,911	23,914
Deferred income tax expense (benefit)	(26,560)	(28,590)
Amortization of debt discount and issuance costs	15,820	16,551
Loss on extinguishment of debt	2,232	1,489
Non-cash lease expense	13,958	14,629
Gain on sale of businesses	—	(28,270)
Other, net	7,405	4,530
Changes in operating assets and liabilities:		
Accounts receivable, net	27,860	114,052
Contract assets, net	4,154	(3,786)
Prepaid expenses and other assets	(37,833)	(48,382)
Accounts payable	7,644	(28,666)
Accrued expenses and other liabilities	(43,743)	27,687
Deferred revenue	(61,832)	36,029
<b>Net cash provided by (used in) operating activities</b>	<b>261,351</b>	<b>296,557</b>
<b>Cash flows from investing activities:</b>		
Capitalized expenditures	(126,828)	(126,432)
Acquisitions, net of cash acquired	—	(439,483)
Proceeds from sale of businesses	—	54,369
Other, net	(1,000)	1,100
<b>Net cash provided by (used in) investing activities</b>	<b>(127,828)</b>	<b>(510,446)</b>
<b>Cash flows from financing activities:</b>		
Payments on Term Loan Facility	(100,000)	(50,000)
Payments under tax receivable agreements	(21,537)	(20,691)
Receipts (payments) on derivative instruments	(14,810)	(14,810)
Employee tax withholding on vesting of equity compensation awards	(18,681)	(3,131)
Payments on deferred financing obligations	(8,981)	(6,547)
Payment of senior amortizing notes	(8,048)	(7,680)
Proceeds from exercise of equity awards	5,985	2,584
Payments on Revolving Facility	—	(250,000)
Proceeds from issuance of Senior Notes	—	325,000
Other, net	(253)	(6,454)
<b>Net cash provided by (used in) financing activities</b>	<b>(166,325)</b>	<b>(31,729)</b>
Effect of exchange rate changes on cash and cash equivalents	115	2,690
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>(32,687)</b>	<b>(242,928)</b>
Cash and cash equivalents at beginning of period	113,101	410,405
<b>Cash and cash equivalents at end of period</b>	<b>\$ 80,414</b>	<b>\$ 167,477</b>

See accompanying notes to consolidated financial statements.

## 1. Nature of Business and Organization

Change Healthcare Inc. (the “Company”, “our” or “we”) is an independent healthcare technology company, focused on accelerating the transformation of the healthcare system through the power of our healthcare platform. We provide data and analytics-driven solutions to improve clinical, financial and patient engagement outcomes in the U.S. healthcare system. Our platform and comprehensive suite of software, analytics, technology-enabled services and network solutions drive improved results in the complex workflows of healthcare system payers and providers by enhancing clinical decision making, simplifying billing, collection and payment processes, and enabling a better patient experience.

We are a Delaware corporation originally formed on June 22, 2016, to initially hold an equity investment in Change Healthcare LLC (the “Joint Venture”), a joint venture between the Company and McKesson Corporation (“McKesson”). Effective July 1, 2019, we completed our initial public offering. The proceeds from the common stock offering were subsequently contributed to the Joint Venture in exchange for additional units of the Joint Venture, which together with the Company’s existing holdings represented an approximate 41% interest in the Joint Venture.

On March 10, 2020, McKesson completed a split-off of its interest in the Joint Venture through an exchange offer of its common stock for shares of PF2 SpinCo, Inc, a Delaware corporation and wholly owned subsidiary of McKesson (“SpinCo”). Immediately following consummation of the exchange offer, SpinCo was merged with and into Change Healthcare Inc. (the “Merger”). Subsequent to the Merger, we own 100% of Change Healthcare LLC, and as a result, consolidate the financial statements of Change Healthcare LLC.

### **UnitedHealth Group Incorporated**

On January 5, 2021, we entered into an Agreement and Plan of Merger (the “UHG Agreement”) with UnitedHealth Group Incorporated (“UnitedHealth Group”), and UnitedHealth Group’s wholly owned subsidiary Cambridge Merger Sub Inc. Pursuant to the UHG Agreement, UnitedHealth Group has agreed to acquire all of the outstanding shares of the Company’s common stock for \$25.75 per share in cash (the “UHG Transaction”). On April 13, 2021, our stockholders approved a proposal to adopt the UHG Agreement, thereby satisfying one of the closing conditions contained in the UHG Agreement. The consummation of the transaction remains subject to the satisfaction or, to the extent permitted by law, waiver of other customary closing conditions.

The UHG Agreement contains representations, warranties, covenants, closing conditions and termination rights customary for transactions of this type. Until the earlier of the termination of the UHG Agreement and the consummation of the UHG Transaction, we have agreed to operate our business in the ordinary course and have agreed to certain other operating covenants, as set forth in the UHG Agreement.

On March 24, 2021, the Company and UnitedHealth Group each received a request for additional information and documentary materials (collectively, the “Second Request”) from the U.S. Department of Justice (the “DOJ”) in connection with the DOJ’s review of the UHG Transaction. The effect of the Second Request is to extend the waiting period imposed under the HSR Act until the 30th day after substantial compliance by the Company and UnitedHealth Group with the Second Request (or such other date upon which substantial compliance is considered effective), unless the waiting period is terminated earlier by the DOJ or extended by the parties to the UHG Transaction. On August 7, 2021, the parties entered into a timing agreement (the “Timing Agreement”) with the DOJ pursuant to which they agreed not to consummate the UHG Transaction before 120 days following the date on which both parties certified substantial compliance with the Second Request.

Both the Company and UnitedHealth Group have now certified substantial compliance with the Second Request. On November 1, 2021, the Company and UnitedHealth Group entered into an amendment to the Timing Agreement with the DOJ pursuant to which they agreed not to consummate the Merger before 12:01 a.m. Eastern Time on February 22, 2022 (subject to extension in certain limited circumstances relating to the potential unavailability of certain requested data), unless they have received written notice from the DOJ prior to such date that the DOJ has closed its investigation. The parties have been working cooperatively with the DOJ and will continue to do so.

### **COVID-19 Considerations**

On March 11, 2020, the World Health Organization declared the coronavirus (“COVID-19”) outbreak to be a global pandemic. In response to this declaration and the rapid spread of COVID-19 within the U.S., federal, state and local governments imposed varying degrees of restrictions on social and commercial activity to promote social distancing in an effort to slow the spread of the illness. These measures led to weakened conditions in many sectors of the economy, including a decline in healthcare transaction volumes that are integral to our business.

In calendar year 2021, the global economy has, with certain setbacks, begun reopening, and wider distribution of vaccines will likely encourage greater economic activity. Nevertheless, we are unable to predict how widely the vaccines will be utilized, whether they will be effective in preventing the spread of COVID-19 (including its variant strains), and the extent to which our

business, results of operations, financial condition or liquidity will ultimately be impacted by COVID-19. However, we are not presently aware of events or circumstances arising from COVID-19 that would require us to revise the carrying value of our assets or liabilities, nor do we expect the impact of COVID-19 to cause us to be unable to comply with our debt covenants or meet our contractual obligations.

## 2. Significant Accounting Policies

### *Basis of Presentation*

The unaudited consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) Guidelines, Rules and Regulations and, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of results for the unaudited interim periods presented. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been omitted. The results of operations for the interim period are not necessarily indicative of the results to be obtained for the full fiscal year. All intercompany accounts and transactions have been eliminated upon consolidation in the unaudited consolidated financial statements.

### *Revenue*

We recognize revenue at an amount that reflects the consideration we expect to be entitled to in exchange for transferring goods or services to a customer, in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). See Note 3, Revenue Recognition, for additional information.

### *Equity Compensation*

We measure stock-based compensation cost based on the estimated fair value of the award on the grant date and recognize the expense over the requisite service period, typically on a straight-line basis. We recognize stock-based compensation expense for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved. The fair value of equity awards is recognized as expense in the same period and in the same manner as if we had paid cash for the goods or services. Forfeitures are recognized as they occur. We issue new shares of common stock upon vesting of equity awards and upon exercise of vested options. We do not intend to repurchase any issued shares of common stock. During the three months ended September 30, 2021 and 2020 we recognized \$23,745 and \$14,331 of equity compensation expense, respectively. During the six months ended September 30, 2021 and 2020 we recognized \$49,911 and \$23,914 of equity compensation expense, respectively. At September 30, 2021, aggregate unrecognized compensation expense related to outstanding awards was \$233,469.

Upon closing of the UHG Transaction, existing awards will generally convert to equivalent UHG awards with consistent vesting provisions. Certain awards will vest upon closing of the UHG Transaction per the terms of the UHG Agreement.

### *Allowance for Credit Losses*

The allowance for credit losses of \$22,833 and \$24,126 at September 30, 2021 and March 31, 2021, respectively, was primarily based on historical credit loss experience, current conditions, future expected credit losses, and adjustments for certain asset-specific risk characteristics. The following table summarizes activity related to the allowance for credit losses:

	<b>Six Months Ended September 30,</b>	
	<b>2021</b>	<b>2020</b>
Balance at beginning of period	\$ 24,126	\$ 22,360
Cumulative effect of accounting change-ASU 2016-13	—	417
Acquisitions and Dispositions <sup>(1)</sup>	—	(1,493)
Provisions	4,312	11,824
Write-offs	(5,605)	(5,080)
Balance at end of period	<u>\$ 22,833</u>	<u>\$ 28,028</u>

<sup>(1)</sup> For the six months ended September 30, 2020, this amount relates primarily to the sale of Connected Analytics.

### **Recently Adopted Accounting Pronouncements**

#### **London Interbank Offered Rate (LIBOR) Reform**

In March 2020, the FASB issued ASU No. 2020-04, as amended by ASU No. 2021-01, which created Topic 848 – Reference Rate Reform. ASU No. 2020-04 contains optional practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts which may be elected over time as activities occur. Among other things, the ASU intends to ease the transition from LIBOR to an alternative reference rate. During the first quarter of fiscal year 2021, we elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. We continue to evaluate the impacts of ASU No. 2020-04 and may apply other elections as reference rate reform activities progress.

#### **Accounting Pronouncements Not Yet Adopted**

##### **Derivatives and Convertible Instruments**

In August 2020, the FASB issued ASU No. 2020-06 which simplifies the accounting for convertible instruments and amends the guidance addressing the derivatives scope exception for contracts in an entity's own equity. The standard is scheduled to be effective for us beginning April 1, 2022. Given the forward purchase contracts of our Tangible Equity Units ("TEUs") qualify for the derivatives scope exception and are currently accounted for under that guidance, we do not expect a material impact upon adoption. We will continue to evaluate the impact of this pronouncement prior to adoption.

### **3. Revenue Recognition**

We generate most of our solutions revenue using technology solutions (generally Software as a Service ("SaaS")) to provide services to our customers that automate and simplify business and administrative functions for payers, providers, pharmacies, and channel partners and through the licensing of software, software systems (consisting of software, hardware and maintenance support) and content. We recognize revenue when the customer obtains control of the good or service through satisfying a performance obligation by transferring the promised good or service to the customer.

#### **Contract Balances**

As of September 30, 2021, we expect 94% of the deferred revenue balance to be recognized in one year or less. Approximately \$273,517 of the balance at the beginning of fiscal year 2022 was recognized during the six months ended September 30, 2021. Approximately \$202,837 of the balance at the beginning of fiscal year 2021 was recognized during the six months ended September 30, 2020.

#### **Remaining Performance Obligations**

The aggregate amount of transaction price allocated to performance obligations that are unsatisfied (or partially unsatisfied) for executed contracts includes deferred revenue and other revenue yet to be recognized from non-cancellable contracts. As of September 30, 2021, remaining performance obligations totaled \$1,380,210, of which 51% is expected to be recognized over the next 12 months, and the remaining 49% thereafter.

In this balance, we do not include the value of unsatisfied performance obligations related to those contracts for which we recognize revenue at the amount for which we have the right to invoice for services performed. Additionally, this balance does not include revenue related to performance obligations that are part of a contract with an original expected duration of one year or less. Lastly, this balance does not include variable consideration allocated to the individual goods or services in a series of distinct goods or services that are substantially the same and that have the same pattern of transfer to the customer. Examples includes variable fees associated with transaction processing and contingent fee services.

#### **Disaggregated Revenue**

We disaggregate the revenue from contracts with customers by operating segment as we believe doing so best depicts how the nature, amount, timing and uncertainty of revenues are affected by economic factors. See Note 16, *Segment Reporting*, for total revenue disaggregated by operating segment for the three and six months ended September 30, 2021 and 2020.

In addition to disaggregating revenue by operating segment, we disaggregate between revenue that is recognized over time and revenue that is recognized at a point in time. For the three and six months ended September 30, 2021, 98% and 96% of revenue was recognized over time, respectively, and 2% and 4% of revenue was recognized at a point in time, respectively. For the three and six months ended September 30, 2020, 97% and 94% of revenue was recognized over time, respectively, and 3% and 6% of revenue was recognized at a point in time, respectively.

#### 4. Business Combinations

##### Fiscal Year 2021 Transactions

###### eRx Network Holdings, Inc.

On May 1, 2020, we exercised our option to purchase and completed the acquisition of 100% of the ownership interest in eRx Network Holdings, Inc. ("eRx"), a leading provider in comprehensive, innovative and secure data-driven solutions for pharmacies. At the time of the acquisition, all outstanding eRx equity awards were canceled and holders of eRx stock options and vested eRx stock appreciation rights were able to elect to receive consideration in the form of a cash payment or vested stock appreciation rights of the Company.

Prior to the acquisition, we held an option to purchase eRx which we accounted for as an equity investment. Therefore, our acquisition of eRx was accounted for as a business combination achieved in stages under the acquisition method in accordance with Accounting Standards Codification 805, *Business Combinations* ("ASC 805"). Accordingly, at the acquisition, we remeasured our business purchase option to fair value and recognized a loss of \$6,000 which is recorded in Other, net on our consolidated statement of operations for the six months ended September 30, 2020.

The following table summarizes information related to this acquisition as of the acquisition date. The fair values of the assets acquired and the liabilities assumed were determined based on information available to the Company using primarily an income-based approach. We consider our accounting for the assets acquired and liabilities assumed in the eRx acquisition to be complete.

	<b>eRx</b>	
Cash paid at closing	\$	249,359
Fair value of eRx purchase option		140,500
Fair value of vested stock appreciation rights		5,097
Cash paid for canceled eRx equity awards		5,891
<b>Total Consideration Fair Value at Acquisition Date</b>	<b>\$</b>	<b>400,847</b>
<b>Allocation of the Consideration Transferred:</b>		
Cash	\$	54,108
Accounts receivable		12,747
Prepaid expenses and other current assets		609
Goodwill		225,156
Identifiable intangible assets:		
Customer relationships (life 17 years)		131,200
Technology-based intangible assets (life 9-12 years)		29,700
Other noncurrent assets		20
Accounts payable		(2,543)
Accrued expenses and other current liabilities		(10,933)
Deferred income tax liabilities		(39,217)
<b>Total consideration transferred</b>	<b>\$</b>	<b>400,847</b>

The goodwill recognized, all of which is assigned to the Network Solutions segment, is primarily attributable to expected synergies of the combined businesses and the acquisition of an assembled workforce knowledgeable of the healthcare and information technology industries. The goodwill is not expected to be deductible for tax purposes. See Note 6, *Goodwill*.

Acquisition costs related to the purchase of eRx were not material.

###### PDX, Inc.

On June 1, 2020, we completed the cash purchase of 100% of the ownership interest in PDX, Inc. ("PDX"), a company focused on delivering patient-centric and innovative technologies for pharmacies and health systems. We accounted for this transaction as a business combination using the acquisition method.

The fair values of the assets acquired and the liabilities assumed were determined based on information available to the Company using primarily an income-based approach. We consider our accounting for the assets acquired and liabilities assumed in the PDX acquisition to be complete.

After customary working capital adjustments, transaction fees and other adjustments, the total consideration fair value at the acquisition date was \$198,291. The following table summarizes the allocation of consideration transferred:

	<b>PDX</b>	
Cash	\$	755
Accounts receivable		5,739
Prepaid expenses and other current assets		2,251
Property and equipment		840
Goodwill		98,830
Identifiable intangible assets:		
Customer relationships (life 18 years)		74,300
Technology-based intangible assets (life 10-11 years)		25,300
Other noncurrent assets		690
Accounts payable		(3,882)
Deferred revenue, current		(2,946)
Accrued expenses and other current liabilities		(3,364)
Other long-term liabilities		(222)
<b>Total consideration transferred</b>	<b>\$</b>	<b>198,291</b>

The goodwill recognized, all of which is assigned to the Network Solutions segment, is primarily attributable to expected synergies of the combined businesses and the acquisition of an assembled workforce knowledgeable of the healthcare and information technology industries. The goodwill is expected to be deductible for tax purposes. See Note 6, *Goodwill*.

Acquisition costs related to the purchase of PDX were not material.

## 5. Dispositions

### *Connected Analytics*

On May 1, 2020, we completed the sale of our Connected Analytics business, which was included in our Software and Analytics segment, for total consideration of \$55,000, subject to a customary working capital adjustment, including a \$25,000 note receivable from the buyer which was recorded within Other noncurrent assets, net on the consolidated balance sheet at June 30, 2020. The net book value of the Connected Analytics business prior to the sale was \$23,428, which includes primarily net accounts receivable of \$16,636, goodwill of \$21,705 and deferred revenue of \$17,083. In connection with this transaction, we recognized a pre-tax gain on disposal of \$24,337 during the year ended March 31, 2021, which was included within Gain on sale of businesses on the consolidated statement of operations. In July 2020, we received \$25,000 plus interest from the buyer in satisfaction of the outstanding note receivable.

### *Capacity Management*

On December 2, 2020, we completed the sale of our Capacity Management business, which was included in our Software and Analytics segment, for total consideration of \$67,500, subject to a customary working capital adjustment. The net book value of the Capacity Management business prior to the sale was \$31,690, which includes primarily net accounts receivable of \$14,991, goodwill of \$26,944 and deferred revenue of \$15,230. In connection with this transaction, we recognized a pre-tax gain on disposal of \$31,690 during the year ended March 31, 2021.

## 6. Goodwill

The following table presents the changes in the carrying amount of goodwill:

	Software and Analytics	Network Solutions	Technology-Enabled Services	Total
<b>Balance at March 31, 2021</b>	\$ 1,758,302	\$ 1,970,739	\$ 379,752	\$ 4,108,792
Acquisitions	—	—	—	—
Dispositions	—	—	—	—
Effects of foreign currency	2,173	—	—	2,173
Adjustments	(142)	—	—	(142)
<b>Balance at September 30, 2021</b>	<u>\$ 1,760,333</u>	<u>\$ 1,970,739</u>	<u>\$ 379,752</u>	<u>\$ 4,110,823</u>

## 7. Long-Term Debt

Long-term debt consists of the following:

	September 30, 2021	March 31, 2021
<i>Senior Credit Facilities</i>		
\$5,100,000 Term Loan Facility, due March 1, 2024, net of unamortized discount of \$71,287 and \$87,698 at September 30, 2021 and March 31, 2021, respectively (effective interest rate of 4.42% and 4.42%, respectively)	\$ 3,321,963	\$ 3,405,552
\$785,000 Revolving Facility, expiring July 3, 2024, and bearing interest at a variable interest rate	—	—
<i>Senior Notes</i>		
\$1,325,000 5.75% Senior Notes due March 1, 2025, net of unamortized discount of \$6,124 and \$6,921 at September 30, 2021 and March 31, 2021, respectively (effective interest rate of 5.90% and 5.90%, respectively)	1,318,876	1,318,079
<i>Tangible Equity Unit Senior Amortizing Note</i>		
\$47,367 Senior Amortizing Notes due June 30, 2022, net of unamortized discount of \$120 and \$293 at September 30, 2021 and March 31, 2021, respectively (effective interest rate of 7.44% and 7.44%, respectively)	12,470	20,345
<i>Other</i>	9,088	18,138
Less current portion	(19,152)	(27,339)
<b>Long-term debt, excluding current portion</b>	<u>\$ 4,643,245</u>	<u>\$ 4,734,775</u>

Our long-term indebtedness includes a senior secured term loan facility (the “Term Loan Facility”) and a revolving credit facility (the “Revolving Facility”; together with the Term Loan Facility, the “Senior Credit Facilities”). The Senior Credit Facilities provide us with the right at any time to request additional term loan tranches and/or term loan increases, increases in the revolving commitments and/or additional revolving credit facilities. Our long-term indebtedness also includes 5.75% senior notes due March 1, 2025 (the “Senior Notes”) with interest payable semi-annually on March 1 and September 1 of each year.

As of September 30, 2021, we were in compliance with all of the applicable covenants under the Senior Credit Facilities and the Senior Notes. In the second quarter of fiscal year 2022, we repaid \$100,000 on our Term Loan Facility and recognized a loss on extinguishment of \$2,232 in our consolidated statement of operations.

## 8. Interest Rate Cap Agreements

### *Risk Management Objective of Using Derivatives*

We are exposed to certain risks arising from both our business operations and economic conditions. We principally manage exposures to a wide variety of business and operational risks through management of core business activities. We manage economic

risks, including interest rate, liquidity and credit risk, primarily by managing the amount, sources and duration of debt funding and the use of derivative financial instruments. Specifically, we enter into derivative financial instrument contracts to manage differences in the amount, timing and duration of known or expected cash receipts and known or expected cash payments principally related to existing borrowings.

#### **Cash Flow Hedges of Interest Rate Risk**

Our objectives in using interest rate derivatives are to add stability to interest expense and to manage exposure to interest rate movements. To accomplish these objectives, we primarily use interest rate cap agreements as part of our interest rate risk management strategy. Payments and receipts related to interest rate cap agreements are included in cash flows from financing activities in the consolidated statements of cash flows.

At September 30, 2021, each of our outstanding interest rate cap agreements were designated as cash flow hedges of interest rate risk and were determined to be highly effective.

Amounts reported in accumulated other comprehensive income related to derivatives will be reclassified to interest expense as interest payments are made on our variable-rate debt. We estimate that \$2,007 will be reclassified as an increase to interest expense within one year.

The fair value of derivative instruments is as follows:

	<b>Fair Values of Derivative Financial Instruments</b>		
	<b>Balance Sheet Location</b>	<b>Asset (Liability)</b>	
<b>Derivative financial instruments designated as hedging instruments:</b>		<b>September 30, 2021</b>	<b>March 31, 2021</b>
Interest rate cap agreements	Other noncurrent assets, net	\$ 8	\$ —
Interest rate cap agreements	Accrued expenses	(8,666)	(22,360)
Interest rate cap agreements	Other long-term liabilities	(53)	(365)
Total		<u>\$ (8,711)</u>	<u>\$ (22,725)</u>

#### **Effect of Derivative Instruments on the Statement of Operations**

The effect of the derivative instruments on the consolidated statements of operations and other comprehensive income (loss) is as follows:

	<b>Three Months Ended</b>		<b>Six Months Ended</b>	
	<b>September 30,</b>		<b>September 30,</b>	
	<b>2021</b>	<b>2020</b>	<b>2021</b>	<b>2020</b>
<b>Derivative financial instruments in cash flow hedging relationships:</b>				
Gain (loss) related to derivative financial instruments recognized in other comprehensive income (loss)	<u>\$ (502)</u>	<u>\$ (2,277)</u>	<u>\$ (796)</u>	<u>\$ (6,737)</u>
(Gain) loss related to portion of derivative financial instruments reclassified from accumulated other comprehensive (income) loss to interest expense	<u>\$ 543</u>	<u>\$ 281</u>	<u>\$ 956</u>	<u>\$ 557</u>

#### **Credit Risk-Related Contingent Features**

We have agreements with each of our derivative counterparties providing that if we default on any of our indebtedness, including a default where repayment of the indebtedness has not been accelerated by the lender, then we also could be declared in default on our derivative obligations.

As of September 30, 2021, the termination value of derivative financial instruments in a net liability position, which includes accrued interest but excludes any adjustment for nonperformance risk, was \$8,857. If we had defaulted on any of our indebtedness at September 30, 2021, we could have been required to settle our obligations under the agreements at this termination value. We do not offset any derivative financial instruments and the derivative financial instruments are not subject to collateral posting requirements.

## 9. Fair Value Measurements

### Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table summarizes our assets and liabilities measured at fair value on a recurring basis, aggregated by the level in the fair value hierarchy within which those measurements fall:

	Total	Quoted in Identical Markets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
<b>Balance at September 30, 2021:</b>				
Interest rate cap agreements	\$ (8,711)	\$ —	\$ (8,711)	\$ —
Total	<u>\$ (8,711)</u>	<u>\$ —</u>	<u>\$ (8,711)</u>	<u>\$ —</u>
<b>Balance at March 31, 2021:</b>				
Interest rate cap agreements	\$ (22,725)	\$ —	\$ (22,725)	\$ —
Total	<u>\$ (22,725)</u>	<u>\$ —</u>	<u>\$ (22,725)</u>	<u>\$ —</u>

### Derivative Financial Instruments

The valuation of our derivative financial instruments is determined using widely accepted valuation techniques, including a discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivative, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair value of the interest rate cap agreements is determined using the market standard methodology of discounting the future expected cash receipts that would occur if variable interest rates rise above the strike rate of the caps. The variable interest rates used in the calculation of projected receipts on the cap are based on an expectation of future interest rates derived from observable market interest rate curves and volatilities.

We incorporate credit valuation adjustments to appropriately reflect both our own nonperformance risk and the respective counterparty's nonperformance risk in the fair value measurements. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we consider the impact of netting and any applicable credit enhancements. We measure the credit risk of our derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio.

Although we have determined that the majority of the inputs used to value our derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments utilize Level 3 inputs to evaluate the likelihood of both our own default and counterparty default. As of September 30, 2021, we determined that the credit valuation adjustments are not significant to the overall valuation of our derivatives and therefore, the valuations are classified in Level 2 of the fair value hierarchy.

### Contingent Consideration

Prior to December 31, 2020, the valuation of our contingent consideration obligation was determined using a discounted cash flow method that involved a Monte Carlo simulation. This analysis reflects the contractual terms of the purchase agreements (i.e., minimum and maximum payments, length of earn-out periods, manner of calculating amounts due, etc.) and utilizes assumptions with regard to future cash flows that were determined using a Monte Carlo simulation which were then discounted to present value using an appropriate discount rate. Significant increases in future revenue assumptions would have resulted in a higher fair value measurement while an increase in the discount rate would have resulted in a lower fair value measurement. The measurement period ended December 31, 2020 at which point no obligations remained and the contingent consideration was reduced to zero.

The table below presents a reconciliation of the fair value of the liabilities that use significant unobservable inputs (Level 3):

	Three Months Ended September 30,		Six Months Ended September 30,	
	2021	2020	2021	2020
Balance at beginning of period	\$ —	\$ (550)	\$ —	\$ (3,000)
Gain (loss) included in Other, net	—	550	—	3,000
Balance at end of period	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>

### Assets and Liabilities Measured at Fair Value upon Initial Recognition

The carrying amount and the fair value of financial instruments held as of September 30, 2021 and March 31, 2021 were as follows:

	September 30, 2021		March 31, 2021	
	Carrying Amount	Fair Value	Carrying Amount	Fair Value
Cash and cash equivalents	\$ 80,414	\$ 80,414	\$ 113,101	\$ 113,101
Senior Credit Facilities (Level 2)	\$ 3,321,963	\$ 3,389,178	\$ 3,405,552	\$ 3,488,883
Senior Notes (Level 2)	\$ 1,318,876	\$ 1,338,250	\$ 1,318,079	\$ 1,351,500
Debt component of tangible equity units (Level 2)	\$ 12,470	\$ 12,896	\$ 20,345	\$ 21,435

As described in Note 4, *Business Combinations*, the assets acquired and liabilities assumed as part of business acquisitions were recorded at fair value upon initial recognition.

### 10. Tangible Equity Units

In July 2019, we completed our offering of 5,750,000 TEUs. Total proceeds, net of underwriting discounts, were \$278,875. Each TEU, which has a stated amount of \$50, is comprised of a stock purchase contract and a senior amortizing note due June 30, 2022. Unless settled earlier, each purchase contract will automatically settle on June 30, 2022. Holders of the purchase contracts may elect to early settle prior to June 30, 2022, at the minimum settlement rate of 3.2051 shares of common stock per purchase contract, resulting in the holder receiving the minimum number of shares for that purchase contract.

In the event of certain types of changes in control (including the consummation of the UHG Transaction) or other specified Reorganization Events (as defined in the TEU agreements), each outstanding purchase contract will convert to a contract entitling the holder to receive cash or other assets that holders of the Company's common stock are entitled to receive in the Reorganization Event. The amount of cash or other assets each holder is entitled to following a Reorganization Event is based on the Applicable Market Value and the corresponding settlement rate in effect at the time.

The following table summarizes TEU activity:

	Tangible Equity Units
<b>Outstanding at March 31, 2020</b>	5,137,345
Issued	—
Conversions	—
<b>Outstanding at September 30, 2020</b>	5,137,345
<b>Outstanding at March 31, 2021</b>	4,833,645
Issued	—
Conversions	(779,325)
<b>Outstanding at September 30, 2021</b>	4,054,320

## 11. Tax Receivable Agreements

As of September 30, 2021, we estimate the aggregate payments due under our tax receivable agreements in future fiscal years to be as follows:

	Related Party Tax Receivable Agreements	McKesson Tax Receivable Agreement	Other Tax Receivable Agreements	Total
Remainder of 2022	\$ —	\$ —	\$ —	\$ —
2023	11,392	24,748	10,761	46,901
2024	10,626	16,478	10,295	37,399
2025	37,213	20,052	16,557	73,822
2026	46,623	57,196	19,350	123,169
Thereafter	63,323	39,785	49,777	152,885
Gross expected payments	169,177	158,259	106,740	434,176
Less: Amounts representing discount	(60,179)	—	(32,803)	(92,982)
Total tax receivable agreement obligations	108,998	158,259	73,937	341,194
Less: Current portion due	(11,392)	(24,748)	(10,761)	(46,901)
Tax receivable agreement long-term obligations	<u>\$ 97,606</u>	<u>\$ 133,511</u>	<u>\$ 63,176</u>	<u>\$ 294,293</u>

The timing and/or amount of aggregate payments due may vary based on a number of factors, including the amount of net operating losses and income tax rates. The amount of aggregate payments shown above do not reflect any potential impacts from the UHG Transaction.

## 12. Income Taxes

The following table summarizes income tax information:

	Three Months Ended September 30,		Six Months Ended September 30,	
	2021	2020	2021	2020
Income tax provision (benefit)	\$ (16,749)	\$ (13,388)	\$ (25,198)	\$ (26,849)
Effective tax rate	31.5%	23.9%	38.6%	20.9%

Fluctuations in our reported income tax rates from the statutory rate are primarily due to the impacts of equity compensation, transaction costs, and benefits recognized for certain incentive tax credits resulting from research and experimental expenditures in the three and six months ended September 30, 2021 and our acquisition and divestiture activity in the three and six months ended September 30, 2020.

## 13. Net Income (Loss) Per Share

The following table sets forth the computation of net income (loss) per share of common stock:

	Three Months Ended September 30,		Six Months Ended September 30,	
	2021	2020	2021	2020
<b>Basic net income (loss) per share:</b>				
Numerator:				
Net income (loss)	\$ (36,404)	\$ (42,622)	\$ (40,009)	\$ (101,316)
Denominator:				
Weighted average common shares outstanding	311,065,959	304,172,412	309,980,392	303,881,424
Minimum shares issuable under purchase contracts	12,994,501	16,465,704	13,328,888	16,465,704
Total weighted average shares outstanding	324,060,460	320,638,116	323,309,280	320,347,128
<b>Basic and diluted net income (loss) per share</b>	<u>\$ (0.11)</u>	<u>\$ (0.13)</u>	<u>\$ (0.12)</u>	<u>\$ (0.32)</u>

Due to their antidilutive effect, the following securities have been excluded from diluted net income (loss) per share:

	Three Months Ended September 30,		Six Months Ended September 30,	
	2021	2020	2021	2020
Restricted Share Units	3,797,124	778,123	4,769,824	875,084
Time-Vesting Options	1,655,445	681,938	1,787,769	636,267
Deferred Stock Units	137,410	61,858	136,509	55,567
Dilutive shares issuable under purchase contracts	—	1,446,935	—	2,369,987

#### 14. Legal Proceedings

We are subject to various claims with customers and vendors, pending and potential legal actions for damages, investigations relating to governmental laws and regulators and other matters arising out of the normal conduct of its business.

##### *UHG Transaction Proceedings*

Following the announcement of the UHG Transaction, nine lawsuits challenging the UHG Transaction were filed in various jurisdictions. The first lawsuit, a putative class action alleging breaches of fiduciary duty, was filed in Tennessee Chancery Court, and was voluntarily dismissed without prejudice on March 17, 2021. The remaining eight lawsuits were filed in federal court between March 18, 2021 and April 7, 2021. The operative complaints in those actions named us and our Board of Directors as defendants and alleged, among other things, that the proxy statement filed in conjunction with the UHG Transaction was materially incomplete and misleading in violation of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 and Rule 14a-9 promulgated thereunder (“Section 14(a) Actions”). All of the Section 14(a) Actions were dismissed without prejudice by April 23, 2021.

We also received written demands from purported stockholders relating to the UHG Transaction. One of the stockholders who made a written demand subsequently filed a complaint against us in the Delaware Court of Chancery on April 13, 2021 pursuant to 8. *Del. C.* § 220, seeking certain books and records relating to the UHG Transaction. That action, which is captioned *Waterford Township Policy & Fire Retirement System v. Change Healthcare, Inc.*, 2021-0317, remains pending and the parties have agreed to stay our deadline to respond to the operative pleading.

##### *Government Subpoenas and Investigations*

From time to time, we may receive subpoenas or requests for information from various government agencies. We generally respond to such subpoenas and requests in a cooperative, thorough and timely manner. These responses sometimes require time and effort and can result in incurring considerable costs. Such subpoenas and requests also can lead to the assertion of claims or the commencement of civil or criminal proceedings against us and other members of the health care industry, as well as to settlements.

##### *Other Matters*

In the ordinary course of business, we are involved in various other claims and legal proceedings. While the ultimate resolution of these matters has yet to be determined, we do not believe that it is reasonably possible that their outcomes will have a material adverse effect on our consolidated financial position, results of operations, or liquidity.

#### 15. Related Party Transactions

##### *Term Loans Held by Related Party*

Affiliates of The Blackstone Group, L.P. (“Blackstone”) were significant stockholders at our inception and continue to hold a material interest in the Company. Certain investment funds managed by GSO Capital Partners LP (the “GSO-managed funds”) held a portion of the term loans under our Senior Credit Facilities. GSO Advisor Holdings LLC (“GSO Advisor”) is the general partner of GSO Capital Partners LP and Blackstone, indirectly through its subsidiaries, holds all of the issued and outstanding equity interests of GSO Advisor. As of September 30, 2021 and March 31, 2021, the GSO-managed funds held \$286,096 and \$162,189, respectively, in principal amount of the Senior Credit Facilities (none of which is classified within current portion of long-term debt).

##### *Transactions with Blackstone Portfolio Companies*

We provide various services to, and purchase services from, certain Blackstone portfolio companies under contracts that were executed in the normal course of business. The following is a summary of revenue recognized and amounts paid related to service provided to and from Blackstone portfolio companies:

	Three Months Ended September 30,		Six Months Ended September 30,	
	2021	2020	2021	2020
Revenue recognized related to services provided	\$ 1,678	\$ 838	\$ 3,448	\$ 1,881
Amount paid related to services received	\$ 4,688	\$ 4,166	\$ 8,941	\$ 9,458

#### ***Employer Healthcare Program Agreement with Equity Healthcare***

Effective January 1, 2014, we entered into an employer health program agreement with Equity Healthcare LLC (“Equity Healthcare”), an affiliate of Blackstone, whereby Equity Healthcare provides certain negotiating, monitoring and other services in connection with our health benefit plans. In consideration for Equity Healthcare’s services, we pay a fee of \$1.00 per participating employee per month.

#### ***eRx Network Option Agreement***

Prior to the creation of the Joint Venture, we entered into an option agreement to acquire eRx (the “Option Agreement”). Under the terms of the Option Agreement, the option to acquire eRx would only become exercisable at any such time that McKesson owns (directly or indirectly), in the aggregate, less than 5% of the outstanding units of the Joint Venture. Subsequent to the Merger, the Option became exercisable and was exercised on May 1, 2020. See Note 4, *Business Combinations*, for additional information.

#### ***Transition Services Agreements***

In connection with the creation of the Joint Venture, we entered into transition services agreements with eRx. Under the agreements, we provided certain transition services to eRx in exchange for specified fees. Prior to the acquisition of eRx, we recognized \$283 in transition fee income during the six months ended September 30, 2020. The amounts received are included in Other, net in the consolidated statement of operations.

## **16. Segment Reporting**

Management views the Company’s operating results based on three reportable segments: Software and Analytics, Network Solutions and Technology-Enabled Services.

#### ***Software and Analytics***

The Software and Analytics segment provides solutions for revenue cycle management, provider network management, payment accuracy, value-based payments, clinical decision support, consumer engagement, risk adjustment and quality performance, and imaging and clinical workflow.

#### ***Network Solutions***

The Network Solutions segment provides solutions for financial, administrative, clinical and pharmacy transactions, electronic payments and aggregation and analytics of clinical and financial data.

#### ***Technology-Enabled Services***

The Technology-Enabled Services segment provides solutions for financial and administrative management, value-based care, communication and payment, pharmacy benefits administration and healthcare consulting.

#### ***Postage and Eliminations***

Postage and eliminations includes pass-through postage costs, as well as eliminations to remove inter-segment revenue and expenses and consolidating adjustments to classify certain rebates paid to channel partners as a reduction of revenue. These administrative costs are excluded from the adjusted EBITDA measure for each respective reportable segment.

#### ***Segment Results***

Revenue and adjusted EBITDA for each of the reportable segments for the three and six months ended September 30, 2021 and 2020 are shown below. Information is reflected in the manner utilized by management to make operating decisions, assess performance and allocate resources. Such amounts include allocations of corporate shared services functions that are essential to the core operations of the reportable segments. Segment assets and related depreciation expenses are not presented to management for purposes of operational decision making, and therefore are not included in the accompanying tables.

	Three Months Ended September 30,		Six Months Ended September 30,	
	2021	2020	2021	2020
<b>Segment Revenue</b>				
Software and Analytics	\$ 363,423	\$ 354,860	\$ 783,740	\$ 746,449
Network Solutions	215,600	184,095	425,061	326,921
Technology-Enabled Services	231,928	231,817	457,450	419,523
Postage and Eliminations <sup>(1)</sup>	19,091	24,073	36,109	51,136
Purchase Accounting Adjustment <sup>(2)</sup>	(3,278)	(38,909)	(7,740)	(93,909)
Net Revenue	<u>\$ 826,764</u>	<u>\$ 755,936</u>	<u>\$ 1,694,620</u>	<u>\$ 1,450,120</u>
<b>Segment Adjusted EBITDA</b>				
Software and Analytics	\$ 112,318	\$ 117,393	\$ 272,683	\$ 261,325
Network Solutions	112,986	94,508	222,474	165,011
Technology-Enabled Services	21,158	19,940	34,033	2,360
Adjusted EBITDA	<u>\$ 246,462</u>	<u>\$ 231,841</u>	<u>\$ 529,190</u>	<u>\$ 428,696</u>
<b>Reconciliation of income (loss) before tax provision (benefit) to Adjusted EBITDA</b>				
Income (loss) before income tax provision (benefit)	\$ (53,153)	\$ (56,010)	\$ (65,207)	\$ (128,165)
Amortization of capitalized software developed for sale	859	12	1,576	89
Depreciation and amortization	163,469	146,869	331,681	285,409
Interest expense	59,466	61,627	118,852	124,294
Equity compensation	23,745	14,331	49,911	23,914
Acquisition accounting adjustments	(1,653)	34,686	(2,212)	83,225
Acquisition and divestiture-related costs	13,765	2,337	20,159	7,458
Integration and related costs	5,933	7,536	17,301	17,894
Strategic initiatives, duplicative and transition costs	14,644	3,765	24,572	8,845
Severance costs	7,303	3,172	12,023	7,876
Accretion and changes in estimate, net	4,355	5,293	9,087	11,188
Impairment of long-lived assets and other	81	7,447	1,692	13,760
Loss on extinguishment of debt	2,232	1,489	2,232	1,489
Gain on sale of businesses	—	(176)	—	(28,270)
Contingent consideration	—	(550)	—	(3,000)
Other non-routine, net	5,416	13	7,523	2,690
Adjusted EBITDA	<u>\$ 246,462</u>	<u>\$ 231,841</u>	<u>\$ 529,190</u>	<u>\$ 428,696</u>

(1) Revenue for the Postage and Eliminations segment includes postage revenue of \$52,550 and \$50,023 for the three months ended September 30, 2021 and 2020, respectively, and \$103,758 and \$95,795 for the six months ended September 30, 2021 and 2020, respectively.

(2) Amount reflects the impact to deferred revenue resulting from the Merger which reduced revenue recognized during the period.

## 17. Accumulated Other Comprehensive Income (Loss)

The following is a summary of the accumulated other comprehensive income (loss) activity. Prior to the Merger, the activity in accumulated other comprehensive income (loss) reflects the Company's proportionate share of the Joint Venture's accumulated other comprehensive income (loss), net of taxes.

	Foreign Currency Translation Adjustment	Cash Flow Hedge	Accumulated Other Comprehensive Income (Loss)
<b>Balance at March 31, 2020</b>	\$ (7,084)	\$ (288)	\$ (7,372)
Change associated with foreign currency translation	6,353	—	6,353
Change associated with current period hedging	—	(4,459)	(4,459)
Reclassification into earnings	—	275	275
<b>Balance at June 30, 2020</b>	<u>\$ (731)</u>	<u>\$ (4,472)</u>	<u>\$ (5,203)</u>
Change associated with foreign currency translation	5,221	—	5,221
Change associated with current period hedging	—	(2,277)	(2,277)
Reclassification into earnings	—	281	281
<b>Balance at September 30, 2020</b>	<u>\$ 4,490</u>	<u>\$ (6,468)</u>	<u>\$ (1,978)</u>
<b>Balance at March 31, 2021</b>	\$ 14,130	\$ (2,909)	\$ 11,221
Change associated with foreign currency translation	3,571	—	3,571
Change associated with current period hedging	—	(294)	(294)
Reclassification into earnings	—	413	413
<b>Balance at June 30, 2021</b>	<u>\$ 17,701</u>	<u>\$ (2,790)</u>	<u>\$ 14,911</u>
Change associated with foreign currency translation	(2,156)	—	(2,156)
Change associated with current period hedging	—	(502)	(502)
Reclassification into earnings	—	543	543
<b>Balance at September 30, 2021</b>	<u>\$ 15,545</u>	<u>\$ (2,749)</u>	<u>\$ 12,796</u>

## 18. Subsequent Events

In October 2021, we made a voluntary repayment on the Term Loan Facility of \$60,000 and recorded a loss on extinguishment of debt of approximately \$1,261.

## ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is intended to help the reader understand our results of operations and financial condition. The MD&A is provided as a supplement to, and should be read in conjunction with, the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2021, as well as the Company's unaudited financial statements and the accompanying notes presented in Item 1 of this Quarterly Report on Form 10-Q.

In addition to historical data, the discussion contains forward-looking statements about the business, operations and financial performance based on current expectations that involve risks, uncertainties and assumptions. Actual results may differ materially from those discussed in the forward-looking statements as a result of various factors, including but not limited to those discussed in *Cautionary Notice Regarding Forward-Looking Statements* and Part II, Item 1A, *Risk Factors*.

### Overview

We are a leading independent healthcare technology company, focused on accelerating the transformation of the healthcare system through the power of our healthcare platform. We provide data and analytics-driven solutions to improve clinical, financial, administrative, and patient engagement outcomes in the U.S. healthcare system.

Our platform and comprehensive suite of software, analytics, technology enabled services and network solutions drive improved results in the complex workflows of healthcare system payers and providers by enhancing clinical decision making, simplifying billing, collection and payment processes, and enabling a better patient experience.

Our healthcare platform supports one of the largest clinical and financial healthcare networks in the U.S. With insights gained from our experience, applications and analytics portfolio and our services operations, we have designed analytics solutions that include industry-leading and trusted franchises supported by extensive intellectual property and regularly updated content.

We were originally formed to hold an equity investment in Change Healthcare LLC (the “Joint Venture”), a joint venture between the Company and McKesson Corporation (“McKesson”). On March 10, 2020, McKesson completed a split-off of its interest in the Joint Venture (“the Merger”). As a result, we own 100% and consolidate the financial statements of Change Healthcare LLC.

## **Recent Developments**

### *The UHG Transaction*

On January 5, 2021, we entered into an Agreement and Plan of Merger (the “UHG Agreement”) with UnitedHealth Group Incorporated (“UnitedHealth Group”), and UnitedHealth Group’s wholly owned subsidiary Cambridge Merger Sub Inc. Pursuant to the UHG Agreement, UnitedHealth Group has agreed to acquire all of the outstanding shares of the Company’s common stock for \$25.75 per share in cash (the “UHG Transaction”). On April 13, 2021, our stockholders approved a proposal to adopt the UHG Agreement, thereby satisfying one of the closing conditions contained in the UHG Agreement. The consummation of the transaction remains subject to the satisfaction or, to the extent permitted by law, waiver of other customary closing conditions.

The UHG Agreement contains representations, warranties, covenants, closing conditions and termination rights customary for transactions of this type. Until the earlier of the termination of the UHG Agreement and the consummation of the transaction, we have agreed to operate our business in the ordinary course and have agreed to certain other operating covenants, as set forth in the UHG Agreement.

On March 24, 2021, the Company and UnitedHealth Group each received a request for additional information and documentary materials (collectively, the “Second Request”) from the U.S. Department of Justice (the “DOJ”) in connection with the DOJ’s review of the UHG Transaction. The effect of the Second Request is to extend the waiting period imposed under the HSR Act until the 30th day after substantial compliance by the Company and UnitedHealth Group with the Second Request (or such other date upon which substantial compliance is considered effective), unless the waiting period is terminated earlier by the DOJ or extended by the parties to the UHG Transaction. On August 7, 2021, the parties entered into a timing agreement (the “Timing Agreement”) with the DOJ pursuant to which they agreed not to consummate the UHG Transaction before 120 days following the date on which both parties certified substantial compliance with the Second Request.

Both the Company and UnitedHealth Group have now certified substantial compliance with the Second Request. On November 1, 2021, the Company and UnitedHealth Group entered into an amendment to the Timing Agreement with the DOJ pursuant to which they agreed not to consummate the Merger before 12:01 a.m. Eastern Time on February 22, 2022 (subject to extension in certain limited circumstances relating to the potential unavailability of certain requested data), unless they have received written notice from the DOJ prior to such date that the DOJ has closed its investigation. The parties have been working cooperatively with the DOJ and will continue to do so.

### *Term Loan Repayment*

In the second quarter of fiscal year 2022, we repaid \$100 million on our Term Loan Facility and recognized a loss on extinguishment of \$2.2 million in our consolidated statement of operations.

## **Key Components of Our Results of Operations**

### *Qualified McKesson Exit*

Prior to the Merger, we accounted for our investment in the Joint Venture using the equity method of accounting. Subsequent to the Merger, we own 100% of the Joint Venture and consolidate its results of operations. We accounted for the Merger as a business combination achieved in stages in accordance with Accounting Standards Codification 805, *Business Combinations* (“ASC 805”). As a result of the accounting for this transaction and the change in basis of accounting, our consolidated results reflect fair value adjustments to various assets and liabilities, including deferred revenue, goodwill, and intangible assets.

### *Segments*

We report our financial results in three reportable segments: Software and Analytics, Network Solutions and Technology-Enabled Services.

- The Software and Analytics segment provides solutions for revenue cycle management, provider network management,

payment accuracy, value-based payments, clinical decision support, consumer engagement, risk adjustment and quality performance, and imaging and clinical workflow.

- The Network Solutions segment provides solutions for financial, administrative, clinical and pharmacy transactions, electronic payments and aggregation and analytics of clinical and financial data.
- The Technology-Enabled Services segment provides solutions for financial and administrative management, value-based care, communication and payment, pharmacy benefits administration and healthcare consulting.

### **Factors Affecting Results of Operations**

The following are certain key factors that affect, will affect, or have recently affected, our results of operations:

#### ***Macroeconomic and Industry Trends***

While conditions have improved since the onset of the COVID-19 pandemic, the spread of COVID-19 has driven lower healthcare utilization as a result of the significant reduction in, or in some cases temporary elimination of, elective medical procedures and healthcare visits, without a corresponding increase in COVID-19 related transactions. A portion of our business is tied to overall volume of activity in the healthcare system, and therefore, we have been adversely impacted by this industry trend. Additionally, unemployment rates continue to be higher than prior to the onset of the COVID-19 pandemic, which has caused commercial payer membership to decline and continues to impact healthcare utilization and transaction volumes.

In response to COVID-19, we initiated a number of actions with our employees' health being our first priority. We also focused on serving our customers and introducing new products and services to address their previously unexpected needs related to COVID-19. While the availability of approved COVID-19 vaccines and their impact on the economy has been encouraging, we cannot predict the length of time it may take for normal healthcare volumes to return and the extent to which our business, results of operations, financial condition or liquidity will ultimately be impacted by COVID-19. However, we continue to assess its impact on our business and are actively managing our response as the pandemic evolves. We believe the solutions we provide our customers will be as important, if not more, post-COVID-19.

#### ***Acquisitions and Divestitures***

Prior to entering into the UHG Agreement, we actively evaluated opportunities to improve and expand our business through targeted acquisitions that are consistent with our strategy. As the UHG Agreement places certain restrictions on the types of acquisitions we can engage in without UnitedHealth Group's consent, we anticipate such activity to be more limited prior to the expected closing of the UHG Transaction. On occasion, and subject to the restrictions set forth in the UHG Agreement, we may also dispose of certain components of our business that no longer fit within our overall strategy. Because of the acquisition and divestiture activity as well as the shifting revenue mix of our business due to this activity, our results of operations may not be directly comparable among periods. See Note 4, *Business Combinations*, and Note 5, *Dispositions*, for details of recent activity.

## Results of Operations

Three Months Ended September 30, 2021 Compared to Three Months Ended September 30, 2020

<i>(amounts in millions)</i> <sup>(1)</sup>	Three Months Ended September 30,		\$	%
	2021	2020		
<b>Revenue</b>				
Solutions revenue	\$ 774.2	\$ 705.9	\$ 68.3	9.7 %
Postage revenue	52.6	50.0	2.6	5.1 %
<b>Total revenue</b>	<b>826.8</b>	<b>755.9</b>	<b>70.9</b>	<b>9.4 %</b>
<b>Operating expenses</b>				
Cost of operations (exclusive of depreciation and amortization below)	\$ 346.6	\$ 326.7	\$ 19.9	6.1 %
Research and development	67.1	54.1	13.0	24.0 %
Sales, marketing, general and administrative	183.0	171.6	11.4	6.7 %
Customer postage	52.6	50.0	2.6	5.1 %
Depreciation and amortization	163.5	146.9	16.6	11.3 %
Accretion and changes in estimate with related parties, net	2.9	3.6	(0.7)	(20.3)%
Gain on sale of businesses	—	(0.2)	0.2	NMF
<b>Total operating expenses</b>	<b>\$ 815.6</b>	<b>\$ 752.6</b>	<b>\$ 63.0</b>	<b>8.4 %</b>
<b>Operating income (loss)</b>	<b>\$ 11.1</b>	<b>\$ 3.3</b>	<b>\$ 7.8</b>	<b>237.3 %</b>
<b>Non-operating (income) expense</b>				
Interest expense, net	59.5	61.6	(2.1)	(3.5)%
Loss on extinguishment of debt	2.2	1.5	0.7	48.8 %
Other, net	2.6	(3.8)	6.4	NMF
<b>Total non-operating (income) expense</b>	<b>\$ 64.3</b>	<b>\$ 59.4</b>	<b>\$ 4.9</b>	<b>8.2 %</b>
<b>Income (loss) before income tax provision (benefit)</b>	<b>(53.2)</b>	<b>(56.0)</b>	<b>2.8</b>	<b>(5.1)%</b>
<b>Income tax provision (benefit)</b>	<b>(16.7)</b>	<b>(13.4)</b>	<b>(3.3)</b>	<b>NMF</b>
<b>Net income (loss)</b>	<b>\$ (36.4)</b>	<b>\$ (42.6)</b>	<b>\$ 6.2</b>	<b>(14.5)%</b>

<sup>(1)</sup> As a result of displaying amounts in millions, rounding differences may exist in the table above.

### Revenue

#### *Solutions revenue*

Solutions revenue increased \$68.3 million for the three months ended September 30, 2021, compared with the same period in the prior year. Factors affecting solutions revenue are described in the various segment discussions below.

#### *Postage revenue*

Postage revenue increased \$2.6 million for the three months ended September 30, 2021, compared with the same period in the prior year. See “Customer postage” below for additional information.

### Operating Expenses

#### *Cost of operations (exclusive of depreciation and amortization)*

Cost of operations increased \$19.9 million for the three months ended September 30, 2021, compared with the same period in the prior year. The increase is primarily attributable to revenue-related expenses.

#### *Research and development*

Research and development expense increased \$13.0 million for the three months ended September 30, 2021, compared with the same period in the prior year. The increase is primarily attributable to investments in product development.

*Sales, marketing, general and administrative*

Sales, marketing, general and administrative expense increased \$11.4 million for the three months ended September 30, 2021, compared with the same period in the prior year, which is primarily attributable to legal fees related to the pending UHG Transaction.

*Customer postage*

Customer postage increased \$2.6 million for the three months ended September 30, 2021, compared with the same period in the prior year. Customer postage is affected by increases in postage rates within communication and payment solutions. Because customer postage is a pass-through cost to our customers, changes in volume of customer postage generally have no effect on operating income.

*Depreciation and amortization*

Depreciation and amortization expense increased \$16.6 million for the three months ended September 30, 2021, compared with the same period in the prior year. Depreciation and amortization were generally affected by routine amortization of tangible and intangible assets existing at March 31, 2021, as well as the routine amortization and depreciation of additions to property, equipment, software and intangible assets since that date.

*Non-Operating Income and Expense*

*Interest expense, net*

Interest expense, net decreased \$2.1 million for the three months ended September 30, 2021, compared with the same period in the prior year. This decrease is primarily attributable to reductions in our average long-term debt outstanding and lower interest rates. While we have interest rate cap agreements in place to limit our exposure to rising interest rates, such agreements, together with our fixed rate notes, effectively fixed interest rates for approximately 81% of our total indebtedness at September 30, 2021.

*Other, net*

Other, net primarily reflects mark to market adjustments on our investments.

*Income Taxes*

Our effective tax rate for the three months ended September 30, 2021 was 31.5% compared to 23.9% for the three months ended September 30, 2020. Fluctuations in our reported income tax rates from the statutory rate are primarily due to the impacts of equity compensation, transaction costs, and benefits recognized for certain incentive tax credits resulting from research and experimental expenditures in the three months ended September 30, 2021.

*Solutions Revenue and Adjusted EBITDA*

<i>(amounts in millions)</i> <sup>(1)</sup>	<b>Three Months Ended September 30,</b>		<b>\$</b>	<b>%</b>
	<b>2021</b>	<b>2020</b>		
<b>Solutions revenue</b> <sup>(2)</sup>				
Software and Analytics	\$ 363.4	\$ 354.9	\$ 8.5	2.4 %
Network Solutions	\$ 215.6	\$ 184.1	\$ 31.5	17.1 %
Technology-Enabled Services	\$ 231.9	\$ 231.8	\$ 0.1	0.1 %
<b>Adjusted EBITDA</b>				
Software and Analytics	\$ 112.3	\$ 117.4	\$ (5.1)	(4.3) %
Network Solutions	\$ 113.0	\$ 94.5	\$ 18.5	19.6 %
Technology-Enabled Services	\$ 21.2	\$ 19.9	\$ 1.3	6.3 %

<sup>(1)</sup> As a result of displaying amounts in millions, rounding differences may exist in the table above.

<sup>(2)</sup> Includes inter-segment revenue and excludes deferred revenue purchase accounting adjustments resulting from the Merger.

*Software and Analytics*

Software and Analytics revenue increased \$8.5 million for the three months ended September 30, 2021, compared with the same period in the prior year. Software and Analytics revenue was positively impacted by volume recovery from COVID-19 related volume declines in the prior period as well as organic revenue growth, which was partially offset by the Capacity Management divestiture which had a revenue impact of \$6.0 million.

Software and Analytics adjusted EBITDA decreased \$5.1 million for the three months ended September 30, 2021, compared with the same period in the prior year. This decrease in adjusted EBITDA primarily reflects the impact of the Capacity Management divestiture and increased product investment, partially offset by the aforementioned revenue growth.

*Network Solutions*

Network Solutions revenue increased \$31.5 million for the three months ended September 30, 2021, compared with the same period in the prior year. Network Solutions revenue was positively impacted by volume recovery and incremental revenue from COVID-19 vaccines and new sales.

Network Solutions adjusted EBITDA increased \$18.5 million for the three months ended September 30, 2021, compared with the same period in the prior year. Network Solutions adjusted EBITDA was impacted by the same factors that impacted revenue, partially offset by investments to support new product launches and market expansion opportunities in the core network and business to business payments offerings.

*Technology-Enabled Services*

Technology-Enabled Services revenue increased \$0.1 million for the three months ended September 30, 2021 as compared with the same period in the prior year. Technology-Enabled Services revenue was impacted by new sales and volume recovery from COVID-19 related volume declines in the prior period, partially offset by customer attrition.

Technology-Enabled Services adjusted EBITDA increased \$1.3 million for the three months ended September 30, 2021 as compared with the same period in the prior year. Technology-Enabled Services adjusted EBITDA was impacted by the same factors that impacted revenue as well as the continued optimization of our cost structure.

Six Months Ended September 30, 2021 Compared to Six Months Ended September 30, 2020

(amounts in millions) <sup>(1)</sup>	Six Months Ended September 30,		\$ Change	% Change
	2021	2020		
<b>Revenue</b>				
Solutions revenue	\$ 1,590.9	\$ 1,354.3	\$ 236.6	17.5%
Postage revenue	103.8	95.8	8.0	8.3%
<b>Total revenue</b>	<b>1,694.6</b>	<b>1,450.1</b>	<b>244.5</b>	<b>16.9%</b>
<b>Operating expenses</b>				
Cost of operations (exclusive of depreciation and amortization below)	\$ 698.7	\$ 645.2	\$ 53.5	8.3%
Research and development	138.3	109.8	28.5	26.0%
Sales, marketing, general and administrative	361.0	337.1	23.9	7.1%
Customer postage	103.8	95.8	8.0	8.3%
Depreciation and amortization	331.7	285.4	46.3	16.2%
Accretion and changes in estimate with related parties, net	5.9	9.5	(3.6)	(37.8)%
Gain on sale of businesses	—	(28.3)	28.3	(100.0)%
<b>Total operating expenses</b>	<b>\$ 1,639.3</b>	<b>\$ 1,454.5</b>	<b>\$ 184.8</b>	<b>12.7%</b>
<b>Operating income (loss)</b>	<b>\$ 55.3</b>	<b>\$ (4.3)</b>	<b>\$ 59.6</b>	<b>NMF</b>
<b>Non-operating (income) expense</b>				
Interest expense, net	118.9	124.3	(5.4)	(4.4)%
Loss on extinguishment of debt	2.2	1.5	0.7	48.8%
Other, net	(0.6)	(2.0)	1.4	NMF
<b>Total non-operating (income) expense</b>	<b>\$ 120.5</b>	<b>\$ 123.8</b>	<b>\$ (3.3)</b>	<b>(2.7)%</b>
<b>Income (loss) before income tax provision (benefit)</b>	<b>(65.2)</b>	<b>(128.2)</b>	<b>63.0</b>	<b>(49.1)%</b>
<b>Income tax provision (benefit)</b>	<b>(25.2)</b>	<b>(26.8)</b>	<b>1.6</b>	<b>(6.0)%</b>
<b>Net income (loss)</b>	<b>\$ (40.0)</b>	<b>\$ (101.3)</b>	<b>\$ 61.3</b>	<b>(60.5)%</b>

(1) As a result of displaying amounts in millions, rounding differences may exist in the table above.

Revenue

*Solutions revenue*

Solutions revenue increased \$236.6 million for the six months ended September 30, 2021, compared with the same period in the prior year. Factors affecting solutions revenue are described in the various segment discussions below.

*Postage revenue*

Postage revenue increased \$8.0 million for the six months ended September 30, 2021, compared with the same period in the prior year. See “Customer postage” below for additional information.

Operating Expenses

*Cost of operations (exclusive of depreciation and amortization)*

Cost of operations increased \$53.5 million for the six months ended September 30, 2021, compared with the same period in the prior year. The increase is primarily attributable to \$32.0 million of revenue-related expenses.

*Research and development*

Research and development expense increased \$28.5 million for the six months ended September 30, 2021, compared with the same period in the prior year. The increase is primarily attributable to recent acquisitions and investments in product development.

### *Sales, marketing, general and administrative*

Sales, marketing, general and administrative expense increased \$23.9 million for the six months ended September 30, 2021, compared with the same period in the prior year, which is primarily attributable to equity compensation and legal fees related to the pending UHG Transaction.

### *Customer postage*

Customer postage increased \$8.0 million for the six months ended September 30, 2021, compared with the same period in the prior year. Customer postage is affected by changes in print volumes and increases in postage rates within communication and payment solutions. Because customer postage is a pass-through cost to our customers, changes in volume of customer postage generally have no effect on operating income.

### *Depreciation and amortization*

Depreciation and amortization expense increased \$46.3 million for the six months ended September 30, 2021, compared with the same period in the prior year. Depreciation and amortization were generally affected by routine amortization of tangible and intangible assets existing at March 31, 2021, as well as the routine amortization and depreciation of additions to property, equipment, software and intangible assets since that date.

### *Gain on sale of businesses*

Gain on sale of businesses decreased \$28.3 million for the six months ended September 30, 2021, compared with the same period in the prior year. This decrease is driven by a gain recorded as a result of the sale of Connected Analytics in May 2020, whereas there was no disposition activity during the six months ended September 30, 2021.

### Non-Operating Income and Expense

#### *Interest expense, net*

Interest expense, net decreased \$5.4 million for the six months ended September 30, 2021, compared with the same period in the prior year. This decrease is primarily attributable to reductions in our average long-term debt outstanding and lower interest rates. While we have interest rate cap agreements in place to limit our exposure to rising interest rates, such agreements, together with our fixed rate notes, effectively fixed interest rates for approximately 81% of our total indebtedness at September 30, 2021.

#### *Other, net*

Other, net primarily reflects mark to market adjustments on our investments.

### Income Taxes

Our effective tax rate for the six months ended September 30, 2021 was 38.6% compared to 23.9% for the six months ended September 30, 2020. Fluctuations in our reported income tax rates from the statutory rate are primarily due to the impacts of equity compensation, transaction costs, and benefits recognized for certain incentive tax credits resulting from research and experimental expenditures in the six months ended September 30, 2021, and our acquisition and divestiture activity in the six months ended September 30, 2020.

<i>(amounts in millions)</i> <sup>(1)</sup>	<b>Six Months Ended September 30,</b>		<b>\$</b>	<b>%</b>
	<b>2021</b>	<b>2020</b>		
<b>Solutions revenue</b> <sup>(2)</sup>				
Software and Analytics	\$ 783.7	\$ 746.4	\$ 37.3	5.0 %
Network Solutions	\$ 425.1	\$ 326.9	\$ 98.2	30.0 %
Technology-Enabled Services	\$ 457.5	\$ 419.5	\$ 38.0	9.0 %
<b>Adjusted EBITDA</b>				
Software and Analytics	\$ 272.7	\$ 261.3	\$ 11.4	4.4 %
Network Solutions	\$ 222.5	\$ 165.0	\$ 57.5	34.8 %
Technology-Enabled Services	\$ 34.0	\$ 2.4	\$ 31.6	NMF

<sup>(1)</sup> As a result of displaying amounts in millions, rounding differences may exist in the table above.

<sup>(2)</sup> Includes inter-segment revenue and excludes deferred revenue purchase accounting adjustments resulting from the Merger.

### *Software and Analytics*

Software and Analytics revenue increased \$37.3 million for the six months ended September 30, 2021, compared with the same period in the prior year. Software and Analytics revenue was positively impacted by volume recovery from COVID-19 related volume declines in the prior period as well as organic revenue growth, which was partially offset by the Connected Analytics and Capacity Management divestitures which had a combined revenue impact of \$21.3 million.

Software and Analytics adjusted EBITDA increased \$11.4 million for the six months ended September 30, 2021, compared with the same period in the prior year. This increase in adjusted EBITDA reflects the aforementioned revenue growth partially offset by the impact of the divestitures.

### *Network Solutions*

Network Solutions revenue increased \$98.2 million for the six months ended September 30, 2021, compared with the same period in the prior year. Network Solutions revenue was positively impacted by volume recovery from COVID-19 related volume declines in the prior period, COVID-19 vaccine volume as well as new sales and the impacts of the eRx and PDX acquisitions which had a combined impact of \$21.6 million, reflecting a full quarter in the first quarter versus a partial first quarter in the prior year.

Network Solutions adjusted EBITDA increased \$57.5 million for the six months ended September 30, 2021, compared with the same period in the prior year. Network Solutions adjusted EBITDA was impacted by the same factors that impacted revenue, partially offset by investments to support new product launches and market expansion opportunities primarily in the core network and business to business payments offerings.

### *Technology-Enabled Services*

Technology-Enabled Services revenue increased \$38.0 million for the six months ended September 30, 2021 as compared with the same period in the prior year. Technology-Enabled Services revenue was positively impacted by volume recovery from COVID-19 related volume declines in the prior period and new sales, partially offset by customer attrition.

Technology-Enabled Services adjusted EBITDA increased \$31.6 million for the six months ended September 30, 2021 as compared with the same period in the prior year. Technology-Enabled Services adjusted EBITDA was impacted by the same factors that impacted revenue as well as the optimization of our cost structure.

### **Significant Changes in Assets and Liabilities**

In addition to the \$100 million repayment on our Term Loan Facility made during the first six months of fiscal year 2022, we regularly receive funds within our Network Solutions segment from certain pharmaceutical industry participants in advance of our obligation to remit these funds to participating retail pharmacies. Such funds are not restricted; however, these funds are generally paid out in satisfaction of the processing obligations within three business days of their receipt. At the time of receipt, we record a corresponding liability within accrued expenses on our consolidated balance sheets. At September 30, 2021, we reported \$20.7 million of such pass-through payment obligations which were subsequently paid in the first week of October 2021. At March 31, 2021, we reported \$16.2 million of such pass-through payment obligations.

### **Liquidity and Capital Resources**

#### **Overview**

Our principal sources of liquidity are cash flows provided by operating activities, cash and cash equivalents on hand, and our Revolving Facility. Our principal uses of liquidity are working capital, capital expenditures, debt service, business acquisitions and other general corporate purposes. Pursuant to the UHG Agreement, however, there are limitations on how we conduct our business during the period from the signing of the UHG Agreement through the close of the transaction, including limitations on our ability to, among other things, engage in certain acquisitions or incur indebtedness. We anticipate our cash on hand, cash generated from operations, and funds available under the Revolving Facility will be sufficient to fund our planned capital expenditures, debt service obligations, permitted business acquisitions and operating needs. Further, we may be required to make additional principal payments on the Term Loan Facility based on excess cash flows of the prior year, as defined in the credit agreement governing the Term Loan Facility.

Cash and cash equivalents totaled \$80.4 million and \$113.1 million at September 30, 2021 and March 31, 2021, respectively, of which \$17.1 million and \$27.7 million was held outside the U.S., respectively. As of September 30, 2021, no amounts had been drawn under the Revolving Facility and \$6.1 million had been issued in letters of credit against the Revolving Facility, leaving \$778.9 million available for borrowing. We also have the ability to borrow up to an additional \$1,736.7 million, or such amount that the senior secured net leverage ratio does not exceed 4.9 to 1.0, whichever is greater, under the Term Loan Facility, subject to certain additional conditions including the UHG Agreement and commitments by existing or new lenders to fund any additional borrowings.

## Cash Flows

The following table summarizes the net cash flow from operating, investing and financing activities:

<i>(amounts in millions)</i> <sup>(1)</sup>	Six Months Ended September 30, 2021	Six Months Ended September 30, 2020	\$ Change	% Change
Cash provided by (used in) operating activities	\$ 261.4	\$ 296.6	\$ (35.2)	(11.9)%
Cash provided by (used in) investing activities	(127.8)	(510.4)	382.6	(75.0)%
Cash provided by (used in) financing activities	(166.3)	(31.7)	(134.6)	424.6%
Effects of exchange rate changes on cash and cash equivalents	0.1	2.7	(2.6)	(96.3)%
<b>Net change in cash and cash equivalents</b>	<b>\$ (32.6)</b>	<b>\$ (242.9)</b>	<b>\$ 210.3</b>	<b>(86.6)%</b>

<sup>(1)</sup> As a result of displaying amounts in millions, rounding differences may exist in the table above.

### Operating Activities

Cash provided by operating activities is primarily affected by operating income, including the impact of debt service payments, integration-related costs and the timing of collections and disbursements. Cash provided by operating activities includes \$4.4 million related to pass-through funds for the six months ended September 30, 2021, and includes a \$1.4 million use of cash related to pass-through funds for the six months ended September 30, 2020.

### Investing Activities

Cash used in investing activities reflects routine capital expenditures related to purchases of property and equipment and the development of software. For the six months ended September 30, 2020, cash used in investing activities also reflects the eRx and PDX acquisitions partially offset by the sale of the Connected Analytics business.

### Financing Activities

Cash used in financing activities reflects payments under the Term Loan Facility, tax receivable agreements, interest rate cap agreements, deferred financing obligations, employee tax withholdings on vesting of equity awards, and tangible equity unit agreements partially offset by proceeds from the exercise of equity awards. Cash provided by financing activities in the prior year reflects the issuance of additional Senior Notes during the six months ended September 30, 2020 partially offset by the repayment of the Revolving Facility during the six months ended September 30, 2020.

### Capital Expenditures

We incur capital expenditures to grow our business by developing new and enhanced capabilities, to increase the effectiveness and efficiency of the organization and to reduce risks. Additionally, we incur capital expenditures for product development, disaster recovery, security enhancements, regulatory compliance and the replacement and upgrade of existing equipment at the end of its useful life.

### Debt

#### Senior Credit Facilities and Senior Notes

In March 2017, the Joint Venture entered into a \$5,100.0 Term Loan Facility and a \$500.0 million Revolving Facility. Additionally, the Joint Venture issued Senior Notes totaling \$1,000.0 million. In July 2019, the Joint Venture amended the Revolving Facility, the primary effects of which were to increase the maximum amount that can be borrowed from \$500.0 million to \$785.0 million and to extend the maturity date until July 2024.

On April 21, 2020, we issued \$325.0 million aggregate principal amount of 5.75% Senior Notes due 2025 (the "Notes"). The Senior Notes were issued as part of the same series as the Senior Notes issued in February 2017.

In second quarter of fiscal year 2022, we repaid \$100 million on our Term Loan Facility and recognized a loss on extinguishment of \$2.2 million.

#### Tangible Equity Units

In connection with our initial public offering in July 2019, we completed an offering of 5,750,000 TEUs. Each TEU, which has a stated amount of \$50.00, is comprised of a stock purchase contract and a senior amortizing note due June 30, 2022. Each senior amortizing note has an initial principal amount of \$8.2378 and bears interest at 5.5% per year. Each year on March 30, June 30, September 30 and December 30, we pay equal quarterly cash installments of \$0.7500 per amortizing note with an aggregate principal

amount of \$47.4 million. Each installment constitutes a payment of interest and partial payment of principal. Unless settled earlier, each purchase contract will automatically settle on June 30, 2022. Holders of TEUs may elect to early settle prior to June 30, 2022, in which case each purchase contract converts to 3.2051 shares of common stock. 779,325 TEUs were converted during the six months ended September 30, 2021.

### Hedges

From time to time, we execute interest rate cap agreements with various counterparties that effectively cap our LIBOR exposure on a portion of our existing Term Loan Facility or similar replacement debt. The following table summarizes the terms of our interest rate cap agreements at September 30, 2021.

Effective Date	Expiration Date	Notional Amount	Receive LIBOR	Pay
			Exceeding <sup>(1)</sup>	Fixed Rate
August 31, 2018	December 31, 2021	\$ 600,000,000	1.00 %	1.82 %
August 31, 2018	December 31, 2021	\$ 900,000,000	1.00 %	1.82 %
March 31, 2020	March 31, 2024	\$ 250,000,000	1.00 %	0.18 %
March 31, 2020	March 31, 2024	\$ 250,000,000	1.00 %	0.18 %
March 31, 2020	March 31, 2024	\$ 250,000,000	1.00 %	0.18 %
March 31, 2020	March 31, 2024	\$ 250,000,000	1.00 %	0.19 %

<sup>(1)</sup> All based on 1-month LIBOR.

The interest rate cap agreements are recorded on the balance sheet at fair value and changes in the fair value are recorded in other comprehensive income (loss). Amounts are reclassified from other comprehensive income (loss) to interest expense in the same period the interest expense on the underlying hedged debt impacts earnings. Any payments we receive to the extent LIBOR exceeds the specified cap rate are also reclassified from other comprehensive income (loss) to interest expense in the period received.

### LIBOR Transition

LIBOR is a commonly used indicative measure of the average interest rate at which major global banks could borrow from one another. On March 5, 2021, the Financial Conduct Authority (“FCA”) (the authority that governs LIBOR) announced that all LIBOR settings will either cease to be provided by any administrator or no longer be representative: (a) immediately after December 31, 2021, in the case of the one week and two-month U.S. dollar settings and (b) immediately after June 30, 2023, in the case of the remaining U.S. dollar settings. The United States Federal Reserve has also advised banks to cease entering into new contracts that use USD LIBOR as a reference rate. The Federal Reserve, in conjunction with the Alternative Reference Rate Committee, a committee convened by the Federal Reserve that includes major market participants, has identified the Secured Overnight Financing Rate, or SOFR, a new index calculated by short-term repurchase agreements, backed by Treasury securities, as its preferred alternative rate for LIBOR. At this time, it is not possible to predict how markets will respond to SOFR or other alternative reference rates as the transition away from the LIBOR benchmarks is anticipated in coming years. Accordingly, the outcome of these reforms is uncertain and any changes in the methods by which LIBOR is determined or regulatory activity related to LIBOR’s phaseout could cause LIBOR to perform differently than in the past or cease to exist. We have material contracts that are indexed to USD-LIBOR and are monitoring this activity and evaluating the related risks.

### Effect of Certain Debt Covenants

A breach of any of the covenants under the agreements governing existing debt could limit our ability to borrow funds under the Term Loan Facility and could result in a default under the Term Loan Facility. Upon the occurrence of an event of default under the Term Loan Facility, the lenders could elect to declare all amounts then outstanding to be immediately due and payable, and the lenders could terminate all commitments to extend further credit. If we were unable to repay the amounts declared due, the lenders could proceed against any collateral granted to them to secure that indebtedness.

With certain exceptions, the Term Loan Facility obligations are secured by a first-priority security interest in substantially all of our assets. The Term Loan Facility contains various restrictions and nonfinancial covenants, along with a senior secured net leverage ratio test. The nonfinancial covenants include restrictions on dividends, investments, dispositions, future borrowings and other specified payments, as well as additional reporting and disclosure requirements. The senior secured net leverage test must be met as a condition to incur additional indebtedness, but otherwise is applicable only to the extent that amounts drawn exceed 35% of the Revolving Facility at the end of any fiscal quarter. As of September 30, 2021, we were in compliance with all debt covenants.

Our ability to meet liquidity needs depends on our subsidiaries’ earnings and cash flows, the terms of our indebtedness along with our subsidiaries’ indebtedness, and other contractual restrictions.

### Cautionary Notice Regarding Forward-Looking Statements

This Quarterly Report contains “forward-looking statements” within the meaning of federal securities laws. Any statements

made in this Quarterly Report that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plans and strategies. These statements often include words such as “anticipate,” “expect,” “suggest,” “plan,” “believe,” “intend,” “estimate,” “target,” “project,” “should,” “could,” “would,” “may,” “will,” “forecast,” “outlook,” “potential,” “continues,” “seeks,” “predicts,” and the negatives of these words and other similar expressions. Although we believe that these forward-looking statements are based on reasonable assumptions, you should be aware that factors affecting our actual financial results could cause actual results to differ materially from those expressed in the forward-looking statements, including those described below.

### **Summary of Material Risks**

Our actual results may differ significantly from any results expressed or implied by any forward-looking statements. A summary of the principal risk factors that make investing in us risky and might cause our actual results to differ is set forth below. The following is only a summary of the principal risks that may materially adversely affect our business, financial condition and results of operations. Factors that could materially affect our financial results or such forward-looking statements include, among others, the following factors:

- the inability to complete the transactions contemplated by the UHG Transaction due to the failure to satisfy the conditions to the completion of the UHG Transaction, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the UHG Transaction;
- risks related to disruption of management’s attention from business operations due to the UHG Transaction;
- the effect of the announcement of the UHG Transaction on our relations with our customers, operations results and business generally;
- the risk that the UHG Transaction will not be consummated in a timely manner, exceeding the expected costs of the UHG Transaction;
- the occurrence of any event, change or other circumstances that could give rise to the termination of the UHG Agreement;
- macroeconomic and industry trends and adverse developments in the debt, consumer credit and financial services markets;
- uncertainty and risks related to the impact of the COVID-19 pandemic (including the rise of COVID-19 variant strains such as the Delta variant) on the national and global economy, our business, suppliers, customers, and employees;
- our ability to retain and recruit key management personnel and other talent (including while the UHG Transaction is pending and in light of our recently imposed COVID-19 vaccine mandate);
- our ability to retain or renew existing customers and attract new customers;
- our ability to connect a large number of payers and providers;
- our ability to provide competitive services and prices while maintaining our margins;
- further consolidation in our end-customer markets;
- our ability to effectively manage our costs;
- our ability to effectively develop and maintain relationships with our channel partners;
- our ability to timely develop new services and improve existing solutions;
- our ability to deliver services timely without interruption;
- a decline in transaction volume in the U.S. healthcare industry;
- our ability to maintain our access to data sources;
- our ability to maintain the security and integrity of our data;
- our reliance on key management personnel;
- our ability to manage and expand our operations and keep up with rapidly changing technologies;
- the ability of our outside service providers and key vendors to fulfill their obligations to us;
- risks related to our international operations;
- our ability to protect and enforce our intellectual property, trade secrets and other forms of unpatented intellectual property;
- our ability to defend our intellectual property from infringement claims by third parties;
- government regulation and changes in the regulatory environment;
- changes in local, state, federal and international laws and regulations, including related to taxation;
- economic and political instability in the U.S. and international markets where we operate;
- litigation or regulatory proceedings;
- losses against which we do not insure;
- our ability to make acquisitions and integrate the operations of acquired businesses;
- our ability to make timely payments of principal and interest on our indebtedness;
- our ability to satisfy covenants in the agreements governing our indebtedness;
- our ability to maintain our liquidity;
- our adoption of new, or amendments to existing, accounting standards;
- the potential dilutive effect of future issuance of shares of our common stock, par value \$0.001 per share (our “common stock”); and

- the impact of anti-takeover provisions in our organizational documents and under Delaware law, which may discourage or delay acquisition attempts.

There may be other factors, many of which are beyond our control, that may cause our actual results to differ materially from the forward-looking statements, including factors disclosed in our Annual Report on Form 10-K for the fiscal year ended March 31, 2021 in the section entitled “Risk Factors” and in the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this report. You should evaluate all forward-looking statements made in this report and the other public statements we may make from time to time in the context of these risks and uncertainties.

Our forward-looking statements made herein speak only as of the date on which made. We expressly disclaim any intent, obligation or undertaking to update or revise any forward-looking statements made herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained in this report.

### **ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

We are exposed to market risk in the normal course of business.

#### **Interest Rate Risk**

We have interest rate risk primarily related to borrowings under our Senior Credit Facilities. Borrowings under the Senior Credit Facilities bear interest at a rate equal to either (i) LIBOR for the relevant interest period, adjusted for statutory reserve requirements (the Term Loan Facility is subject to a floor of 1.00% per year and the Revolving Facility is subject to a floor of 0.00% per year), plus an applicable margin or (ii) a base rate equal to the highest of (a) the rate of interest in effect as publicly announced by the administrative agent as its prime rate, (b) the federal funds effective rate plus 0.50% and (c) adjusted LIBOR for an interest period of one month plus 1.00% (the Term Loan Facility may be subject to a floor of 2.00% per year), in each case, plus an applicable margin.

As of September 30, 2021, we had Term Loan Facility borrowings of \$3,493.3 million (before unamortized debt discount) and no Revolving Facility borrowings. As of September 30, 2021, the LIBOR-based interest rate on the Term Loan Facility was LIBOR plus 2.5%.

We manage economic risks, including interest rate, liquidity and credit risk, primarily by managing the amount, sources and duration of our debt funding and the use of derivative financial instruments. Specifically, we enter into interest rate cap agreements to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. Our interest rate cap agreements are used to manage differences in the amount, timing and duration of our known or expected cash receipts and our known or expected cash payments principally related to our borrowings. As of September 30, 2021, our outstanding interest rate cap agreements were designated as cash flow hedges of interest rate risk and were determined to be highly effective.

A change in interest rates on variable rate debt may impact our pretax earnings and cash flows. Based on the outstanding debt as of September 30, 2021, and assuming that our mix of debt instruments, derivative financial instruments and other variables remain the same, the annualized effect of a one percentage point change in variable interest rates would have an annualized pretax impact on the earnings and cash flows of approximately \$1.2 million.

In the future, in order to manage our interest rate risk, we may refinance existing debt, enter into additional interest rate cap agreements, modify our existing interest rate cap agreements or make changes that may impact our ability to treat our interest rate cap agreements as a cash flow hedge. However, we do not intend or expect to enter into derivative or interest rate cap agreement transactions for speculative purposes.

### **ITEM 4. CONTROLS AND PROCEDURES**

#### **Evaluation of Disclosure Controls and Procedures**

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2021. The term “disclosure controls and procedures” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (“the Exchange Act”) means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to management including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely discussions regarding required disclosures.

Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving their desired control objectives. Based on the evaluation of disclosure controls and procedures as of September 30, 2021, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at a reasonable assurance level.

### **Changes in Internal Control over Financial Reporting**

During the quarter ended September 30, 2021, there have been no changes in the Company's internal controls over financial reporting that have materially affected or are reasonably likely to materially affect, the Company's internal controls over financial reporting.

## **PART II. OTHER INFORMATION**

### **ITEM 1. LEGAL PROCEEDINGS**

We are involved in legal proceedings related to the potential UHG Transaction and various other legal proceedings in the ordinary course of business. We believe that the ultimate disposition of such proceedings will not have a material adverse effect on our consolidated financial position, results of operations or liquidity. See Note 14, *Legal Proceedings*, to our consolidated financial statements.

### **ITEM 1A. RISK FACTORS**

In addition to the other information included in this report, you should carefully consider the factors discussed in the section entitled "Risk Factors" included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2021 ("the Annual Report"), as well as the factors identified under "Cautionary Notice Regarding Forward-Looking Statements" at the end of Part I, Item 2 of this Quarterly Report, which could have a material adverse impact on our business, financial condition or operating results. There have been no material changes to the risk factors described in the Annual Report. The risks described in the Annual Report and this Quarterly Report are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition or operating results.

### **ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

None.

### **ITEM 3. DEFAULTS UPON SENIOR SECURITIES**

None.

### **ITEM 4. MINE SAFETY DISCLOSURES**

None.

### **ITEM 5. OTHER INFORMATION**

None.

### **ITEM 6. EXHIBITS**

The exhibits listed on the accompanying Exhibit Index are filed, furnished or incorporated by references (as stated therein) as part of this Quarterly Report.

## Exhibit Index

Exhibit No.	Description
2.1	<a href="#">Agreement and Plan of Merger, dated as of January 5, 2021, by and among Change Healthcare Inc., UnitedHealth Group Incorporated and Cambridge Merger Sub Inc. (incorporated by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed on January 6, 2021)</a>
3.1	<a href="#">Amended and Restated Certificate of Incorporation of Change Healthcare Inc., dated as of June 26, 2019 (incorporated by reference to Exhibit 3.1 to the Company's Registration Statement on Form S-4 on February 4, 2020)</a>
3.2	<a href="#">Amended and Restated Bylaws of Change Healthcare Inc., dated as of June 26, 2019 (incorporated by reference to Exhibit 3.2 to the Company's Registration Statement on Form S-4 filed on February 4, 2020)</a>
31.1*	<a href="#">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended</a>
31.2*	<a href="#">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended</a>
32.1*	<a href="#">Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a>
32.2*	<a href="#">Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a>
101.INS*	iXBRL Instance Document
101.SCH*	iXBRL Taxonomy Extension Schema Document
101.DEF*	iXBRL Taxonomy Extension Definition Linkbase Document
101.CAL*	iXBRL Taxonomy Extension Calculation Linkbase Document
101.LAB*	iXBRL Taxonomy Extension Label Linkbase Document
101.PRE*	iXBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted as iXBRL and contained in Exhibits 101)

\* Filed herewith.

Certain agreements and other documents filed as exhibits to this Form 10-Q contain representations and warranties that the parties thereto made to each other. These representations and warranties have been made solely for the benefit of the other parties to such agreements and may have been qualified by certain information that has been disclosed to the other parties to such agreements and other documents and that may not be reflected in such agreements and other documents. In addition, these representations and warranties may be intended as a way of allocating risks among parties if the statements contained therein prove to be incorrect, rather than as actual statements of fact. Accordingly, there can be no reliance on any such representations and warranties as characterizations of the actual state of facts. Moreover, information concerning the subject matter of any such representations and warranties may have changed since the date of such agreements and other documents.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CHANGE HEALTHCARE INC.

Date: November 4, 2021

By: /s/ Neil E. de Crescenzo  
Neil E. de Crescenzo  
Chief Executive Officer and Director  
(Principal Executive Officer)

Date: November 4, 2021

By: /s/ Fredrik Eliasson  
Fredrik Eliasson  
Executive Vice President, Chief Financial Officer  
(Principal Financial Officer)

## SARBANES-OXLEY SECTION 302(a) CERTIFICATION

I, Neil E. de Crescenzo, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Change Healthcare Inc. (the “registrant”);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
  - a. Designed such disclosure control and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
  - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
  - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 4, 2021

By: /s/ Neil E. de Crescenzo  
Name: Neil E. de Crescenzo  
Title: President and Chief Executive Officer of Change  
Healthcare Inc.

---

## SARBANES-OXLEY SECTION 302(a) CERTIFICATION

I, Fredrik Eliasson, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Change Healthcare Inc. (the “registrant”);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
  - a. Designed such disclosure control and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
  - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
  - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 4, 2021

By: /s/ Fredrik Eliasson

Name: Fredrik Eliasson

Title: Executive Vice President and Chief Financial Officer of Change Healthcare Inc.

---



**CERTIFICATION PURSUANT TO  
18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Change Healthcare Inc. (the "Company") on Form 10-Q for the fiscal quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Fredrik Eliasson, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an officer of the Company, that, to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 4, 2021

By: /s/ Fredrik Eliasson

Name: Fredrik Eliasson

Title: Executive Vice President and Chief Financial  
Officer of Change Healthcare Inc.

---